Einträge von Rittmeyer, Achim auf dem Publikationsserver

Lee, Siow Ming, Schulz, Christian, Prabhash, Kumar, Kowalski, Dariusz, Szczesna, Aleksandra, Han, Baohui, Rittmeyer, Achim, Talbot, Toby, Vicente, David, Califano, Raffaele, Cortinovis, Diego, Le, Anh Tuan, Huang, Dingzhi, Liu, Geoffrey, Cappuzzo, Federico, Reyes Contreras, Jessica, Reck, Martin, Palmero, Ramon, Mak, Milena Perez, Hu, Youyou, Morris, Stefanie, Höglander, Elen, Connors, Mary, Biggane, Alice M, Vollan, Hans Kristian und Peters, Solange (2023) First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. The Lancet 402 (10400), S. 451-463. Volltext nicht vorhanden.

Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A., Shen, Robert, Tjulandin, Sergei A., Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G. und Lehmann, Frédéric F. (2016) Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study. Journal of Thoracic Oncology 11 (12), S. 2208-2217. Volltext nicht vorhanden.